

FKMCD-Oxitec Public Educational Webinar #7 Human Health and Oxitec: The Safety of Oxitec Technology



OXITEC

27 October 2020

Introductions – Panelists With You Today





Andrea Leal Executive Director FKMCD



Meredith Fensom Head of Public Affairs Oxitec



Kevin Gorman Head of Field Operations Oxitec



Nathan Rose Head of Regulatory Affairs Oxitec



FKMCD and Oxitec are hosting a series of public educational webinars to share information with residents of the Florida Keys and provide forums to answer questions.

- All webinars are open to everyone
- All webinars are recorded and made available for everyone after the event
- All questions will be answered (some in batches if questions are similar)
- If time runs out, we will accept questions in writing via <u>florida@oxitec.com</u>
- Questions and answers will be published in writing after the event with external or related online resources/references

Upcoming:

- **1.** Virtual Tour: Inside Oxitec Labs coming in <u>November</u>! Meet the team that produces mosquitoes for the project and see inside one of Oxitec's production facilities in a virtual tour.
- 2. What's in the Box?: How Oxitec's Just-Add-Water Technology Helps Control the Aedes aegypti Population coming in December!
- 3. Preparing for the FKMCD-Oxitec Pilot Project: Overview of Field Trial Design and Management coming in January!



Florida Keys & Oxiter Public Educational Webinars



Welcome to Webinar #7!

Today's Agenda:

- Why now? Health, economy and the environment.
- Disease transmission by the invasive *Aedes aegypti* mosquito.
- Current options for mosquito control.
- Benefits of Oxitec's targeted biological control solution.
- Safety of Oxitec's OX5034 male mosquitoes.
- Regulatory findings.
- Your questions, answered.





- Dengue is an ongoing challenge with over 65 confirmed locally-acquired cases in Monroe County so far in 2020
- The threat of other diseases such as Zika, chikungunya and yellow fever persists
- Insecticide resistance in local mosquitoes
- Need more tools in our toolbox
- Environmental impact is a major consideration, including for human health
- Using species-specific tools minimizes harmful impacts
- Nine national and state agencies concluded Oxitec male mosquitoes pose no risk to human or environmental health
- More than one billion Oxitec mosquitoes have been produced for release worldwide, with no negative impacts

Dengue Cases in Florida Since 1987 400 300 200 Imported Case 100 Locally Acquired Case 2007 2012 1987 1992 1997 2002 2017 FLORIDA DEPARTMENT OF HEALTH *As of 10/27/2020



Endangered Schaus' swallowtail butterfly lives where the current dengue outbreak is.

Dengue, Chikungunya, Zika, Yellow Fever

Dengue, Chikungunya, Zika, Yellow Fever and other viruses are all transmitted by female *Aedes aegypti* mosquitoes. Only Yellow Fever has an effective vaccine available.





Symptoms of these viruses range from mild to severe.

- Dengue Hemorrhagic Fever (DHF) is a severe form of dengue that may be life-threatening.
- Zika may result in microcephaly in babies.

The Aedes aegypti Mosquito: an Invasive Species in Florida



Aedes aegypti is not native to the Americas. It was most likely transported from Africa by Portuguese ships sometime in the 16th century, **bringing viral diseases with it.**

OXITEC



Current Options for Aedes aegypti Control



- Insecticides (pyrethroids, organophosphates), with resistance an increasing problem
- Aerial *Bti* spraying

OXITEC

Breeding site disruption/removal

Oxitec's Aedes aegypti Mosquito Technology ("OX5034")



• No females produced

ΟΧΙΤΕΟ

• Low-tech, egg-based devices enabled





- Easy track-and-trace in the field
- Non-toxic, non-allergenic



Do Oxitec Mosquitoes Bite?



The LA Line

ADDEDBICA NO CLANES

10)

Oxitec mosquitoes do not bite.

Only female mosquitoes bite. There will be no Oxitec female mosquitoes.

Oxitec male mosquitoes are safe and non-toxic.

MALE MOSQUITOES CANNOT BITE

FEMALE:	MALE:	
Biting	Non-biting	mo
mouthparts	mouthparts	0
	152/	me
	V	mk
		_ pr _ ur
		bit

The mouthparts of males mean they are physically unable to bite people

DXITEC How Does the Self-Limiting Gene Work?

SELF-LIMITING FEATURES:

- Females cannot survive
- Male OX5034 mosquitoes are unaffected:
 - Male-only production;
 - Egg release devices;
 - Suppression of wild mosquito populations, as female offspring cannot survive.

Zero OX5034 females released

Males are unaffected





20 million

male OX5034 mosquitoes released in Brazil

1 billion

OX513A mosquitoes produced for release globally

Zero Negative Impact

DALTEC How Does the Fluorescent Marker Gene Work?



- Allows us to track Oxitec mosquitoes after release
- Widely used in biology for 20 years
- Produced in OX5034 mosquitoes at all life stages
- Male OX5034 mosquitoes can pass on the gene to their offspring

Non-toxic, non-allergenic protein that is visible under special filters





ELOR/D

Background Genetic Introgression



The EPA and CDC reviewed the impact of 'introgressing' background genes, concluding there was no risk to human health or the environment and no risk of "hybrid vigor".







- + NO HYBRID VIGOR
- Regulatory Agencies Confirmed + NC
 - + NO INSECTICIDE RESISTANCE
 - + NO ADDED VECTORIAL CAPACITY





Beer



Medicines



Fruit

Biotechnology is Everywhere in Public Health and Everyday Life

Vegetables and Grain

OXITEC Overview of EPA's Scientific Assessment & Approval



Key Elements:

- 14-month in-depth process
- Exhaustive scientific review
- Risk assessment
- Multi-agency support
- Public comment & responses

By the Numbers:

- 70+ documents submitted
- 25 commissioned studies
- 4,500+ pages, including 2,500+ pages of scientific peer-reviewed literature



Data Requirements Fulfilled by Oxitec (partial list)

Environmental Assessments*:	Health Assessments:	Mosquito Characterization and Performance:	
 Fish Birds Mammals Plants Aquatic Invertebrates Insects Endangered Species 	 Trait Penetrance Oral Toxicity Inhalation Toxicity Ocular Toxicity Dermal Toxicity Allergenicity Vector Competence 	 Insecticide Susceptibility Trait Penetrance Tetracycline Response Stability of Genetic Traits Trait Persistence Field Data (Brazil) 	 Protein Stability Arbovirus Screening Introgression Analysis Complete SOPs Analytical Methodologies

We Continue to Invite Comprehensive Independent Reviews OXITEC



DEPARTMENT OF HEALTH & HUMAN SERVICES

Mr. Grey Frandsen Chief Executive Officer Oxitec Ltd 71 Innovation Drive Milton Park United Kingdom OX144RO grey@oxitec.com

Dear Mr. Frandsen,

Thank you for informing us of your proposed collaboration with the Florida Keys Mosquito Control Board in the coming year. We understand that the proposed pilot project would leverage the Experimental Use Permit that EPA recently granted to pilot Oxitec's 2nd generation FriendlyTM Aedes aegypti mosquito technology to reduce mosquito populations in the Florida Keys over the spring and summer of 2021.

CDC is committed to identifying novel tools for preventing and controlling vector-home diseases, including those caused by the bite of infected Aedes aegypti mosquitoes. As new technologies like the Oxitec technology are developed and gain EPA approval, it is very important to carefully evaluate the impact of early implementations. The results of these evaluations will inform CDC's future guidance on mosquito control and will directly impact future decisions made by local and state health departments about the value of these technologies for use towards the prevention and control of mosquito-borne diseases.

For these reasons, I am writing this letter to communicate our intention to collaborate with you and the jurisdiction on the evaluation of this important project. If approved by the Florida Keys Mosquito Control Board, entomologists and senior leaders from CDC's Division of Vector-Borne Diseases (DVBD) will provide their technical assistance to develop a strong project evaluation. The evaluation will be designed to ensure that collaborators from Oxitec and the jurisdiction can draw defendable conclusions about the impact of the implementation on mosquito populations. These data are needed to inform the field and local decision-makers so that evidence-based decisions can be made about future implementations.

Sincerely

Lyle R. Petersen, MD, MPH Director Division of Vector-Borne Diseases CDC National Center for Emerging and Zoonotic Infectious Diseases (970) 221-6428 LXP2@cdc.gov





CENTERS FOR DISEASE CONTROL AND PREVENTION

CDC confirms participation:

"...I am writing this letter to communicate our intention to collaborate with you and the jurisdiction on the evaluation of this important project.

...entomologists and senior leaders from CDC's Division of Vector-Borne Diseases (DVBD) will provide their technical assistance to develop a strong project evaluation."

Lyle Petersen, MD, MPH Director of Division of Vector-Borne Diseases Centers for Disease Control and Prevention

How Are OX5034 Mosquitoes Produced in the UK?

OXITEC





BOXES ARE PLACED BY FKMCD/OXITEC OPERATORS



- ✓ No female release & no biting
- ✓ Only male adults in the box
- ✓ No tetracycline in the box
- ✓ No tetracycline in Florida
- Boxes will be placed in out-ofthe-way areas

Tetracycline: EPA, FDA Confirm Oxitec Mosquitoes Pose No Risk





OXITEC

EPA has concluded that "there is negligible risk that testing of OX5034 mosquitoes would spread antibiotic resistant bacteria in the US environment"

FDA has previously concluded that "the likelihood of the adverse effects associated with development of anti-microbial resistance is extremely low."

- + Eggs shipped to Florida have never been in contact with tetracycline
- To produce all the eggs required for this project in the UK, Oxitec will use less tetracycline than sugar in a packet, equivalent to two human therapeutic courses



In the USA, every year:

- Doctors' offices and emergency departments prescribe about 47 million antibiotic courses for infections that don't need antibiotics (<u>CDC</u>)
- Nearly 4,000 tons supplied to livestock and pets (FDA)

In Florida:

- Up to 388,000 lbs of oxytetracycline approved for spraying each year on 300,000+ acres of citrus farms since 2015 (<u>EPA</u>)
- Use of tetracyclines on farms and in human medicine is linked to resistant bacteria in waterways and coastal waters¹, and marine wildlife²
 ¹https://www.mdpi.com/2079-6382/9/3/118/htm ²Schaefer et al, 2009 Ecohealth 6: 33–41.



20

- Published peak suppression performance of wild-type Aedes aegypti ranging from 92% to 96% as compared to control sites (see below)
- 1Bn+ Oxitec mosquitoes produced for release with no adverse effect on humans or the environment
- Deployments ranged from small-scale to coverage of 65K people

- Successful suppression of target Aedes aegypti populations in range of deployments
- Demonstrated safe with no lasting impact on the environment, humans or animals
- Multiple pilot approvals from biosafety regulators







EUP Approved By:

- ✓ US Federal EPA (with CDC expert reviews)
- Florida Department of Agriculture and Consumer Services
- Florida Department of Environmental Protection (FDEP)
- Florida Fish and Wildlife Conservation Commission (FWC)
- Bureau of Inspection and Incident Response (BIIR)
- Florida Department of Health (DOH)
- Bureau of Agricultural Environmental Laboratories (BAEL)
- Bureau of Chemical Residue Laboratories (BCRL)
- Bureau of Scientific Evaluation and Technical Assistance, Scientific Evaluation Section (SES)

Further endorsement:

World Health Organization

In 2016, following the declaration of a public health emergency of international concern, the World Health Organization recommended Oxitec mosquitoes for pilot deployment to fight the growing threat posed by the Zika virus





- An increasing disease threat is evident.
- Protecting against an invasive species is important.
- Oxitec's non-biting male mosquitoes pose no risks to human health.
 - Male mosquitoes are harmless to humans, they cannot bite people or spread disease.
 - More than one billion Oxitec mosquitoes produced for release worldwide, with no negative impacts.
- OX5034 could reverse increasing resistance to insecticides.







Question and Answers



Any and all questions on this evening's topics are welcome!

(If we run out of time tonight, email <u>florida@oxitec.com</u> and we will attempt to answer your question if it isn't included in the growing FAQ or post-event summary we publish online at <u>oxitec.com/florida</u> and <u>keysmosquitoproject.com</u>)



Conclusion



THANK YOU!

A summary of this event, as well as more Q&As, resources, facts, and background materials are available at <u>oxitec.com/florida</u> and <u>keysmosquitoproject.com</u>.